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LOMA LINDA UNIVERSITY CENTER FOR CHRISTIAN BIOETHICS 
TAKANOBU KINJO, SCOTT 
WINTERS AND NICOLE 
WURSCHER GRADUATE 
WITH DEGREES IN ETHICS 
AND MINISTRY 
Takanobu Kinjo of Okinawa, Japan, 
pd Nicole Elizabeth Wurscher from the 
"tate of Washington received their MA 
degrees in biomedical and clinical ethics 
from Lorna Linda University in August 
of this year. Scott Keith Winters, from 
Lincoln, Nebraska, received an MA 
degree in clinical ministry the same 
month. He was the first student to 
receive this degree from LLU. 
Mr. Kinjo, Mr. Winters, and Ms. 
Wurscher are three of the 1,192 under-
graduate and graduate students to grad-
uate from Lorna Linda University in 
2000. The others are receiving degrees 
and certificates in the allied health pro-
fessions, dentistry, medicine, nursing, 
public health, and the natural and 
behavioral sciences. 
The graduations of Mr. Kinjo and 
~1s. Wurscher bring the number of those 
who have completed the MA degree in 
ethics at LLU to seventeen. Eighteen 
graduate students are now working 
toward this degree. Thirteen are work-
ing toward the MA degree in clinical 
ministry. L Mr. Kinjo, who graduated from La 
Sierra University in 1996 with an under-
graduate degree in psychology, antici-
pates returning to Japan for a while 
before continuing his education either 
Volume 16, Number 2 (September 2000) 
in the United States or in the United 
Kingdom. Ms. Wurscher, who graduated 
with a bachelors degree in biology from 
Walla Walla College in 1998, plans to 
continue her career and education in this 
country. Mr. Winters, who received his 
BA degree in 1993 from Union College 
in Nebraska, plans to finish his Clinical 
Pastoral Education at Sutter Medical 
Center in Sacramento. 
Mr. Kinjo wrote a thesis analyzing 
recent controversies in Japan regarding 
whole brain death criteria and organ 
transplantation. For her final project, Ms. 
Wurscher designed a web site for dental 
ethics and prepared two papers. One of 
these reviews recent debates in the 
United States about "medical futility" 
and the other discusses ways to make 
advance medical directives more effec-
tive. Mr. Winters did a final project on 
spirituality and values clarification ... 
DOCTOR ORR'S RELIGION: GOOD, 
NOT-SO-GOOD, AND VERY GOOD! 
Note: David R. Larson made the fol-
lowing remarks at an August farewell gath-
ering in honor of Dr. and Mrs. Robert Orr 
at Lama Linda University Medical Center. 
For me, as for all of you, it has been 
a great pleasure to work with Dr. 
Robert Orr at Lorna Linda University 
for the past ten years. It seems like 
only yesterday that I was in St. Louis 
for meetings of the Society for 
Bioethics Consultation. While there I 
had an opportunity to ask Dr. Mark 
Continued on page 7 
ROBERT AND JOYCE ORR 
RETURN TO VERMONT 
Dr. and Mrs. Robert D. Orr have 
returned to Vermont, the state they 
call "home." It is also where all three 
of their adult children now reside. Dr. 
Orr, who has served as the director of 
clinical ethics at Lorna Linda 
U niversity ~1edical Center since 1990, 
has accepted a similar position at the 
University of Vermont. 
Dr. Orr received his undergradu-
ate education at Houghton College in 
New York. He studied medicine at 
McGill University in Canada. After 
serving as a physician in the Navy, he 
practiced family medicine for a 
number of years in Vermont where he 
was named "family physician" for the 
entire state. 
After their years of service in 
Vermont, the Orrs moved to the 
Midwestern portion of the United 
States where Dr. Orr studied clinical 
Continued on page 8 
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Medical Theodicy Today 
by Richard Rice 
The wonderful title of a new book 
aptly expresses the goal of its contents. 
Pain Seeking Understanding, edited by 
Margaret E. Mohrmann and Mark J. 
Hanson (Cleveland: Pilgrim Press, 
1999) is neither a book on theodicy per 
se, nor a how-to book for sufferers or 
caregivers. Instead, it probes an area 
between these concerns-the relation 
between theological convictions and 
the practical demands of medical care. 
It is therefore an example of "medical 
theodicy," or, as ,David Larson nicely 
puts it, "theodicy with a clinical edge." 
This book contains essays by 
twelve different scholars, including 
physicians, theologians, philosophers, 
and ethicists. Part 1, "Clinical 
Perspectives," looks at the ways specif-
ic individuals come to terms with suf-
fering. The authors argue that sufferers 
seek a meaning that is practical rather 
than theoretical, partial rather than 
comprehensive. A medical theodicy, 
then, is "practical, experiential, and 
paradoxical." Rather than reconciling 
abstract propositions about God, it 
seeks to make things of form and beau-
ty out of lived anxiety and pain. 






sents some contrasting theological-
philosophical approaches to suffering. 
Does traditional theodicy have practi-
cal value? Daniel P. Sulmasy says yes, 
and construes suffering as an 
inescapable experience of human fini-
tude. Wendy Farley says no. "Suffering 
does not require explanation so much 
as redemption." Accordingly, compas-
sion is theodicy's ultimate work. We 
should be present to one another in our 
suffering just as God is radically pre-
sent to us. Elliot N. Dorff discusses the 
Jewish emphasis on the body as inte-
gral to the person and the important 
practice of visiting the sick. Per 
Anderson, drawing on Reinhold 
Niebuhr's so-called "serenity prayer," 
argues that we can help people accept 
and find meaning in things that cannot 
be changed, contra the attitude that 
pervasive technology engenders. 
Part 3 examines several diverse 
issues-the "secular problem of evil" 
the fact that all of us, religious or not, 
face the twin obligations of relieving 
the suffering of others and fulfilling our 
own potential as persons; the response 
of Christian faith to genetic testing, 
with its fatalistic overtones; and the 
need for bioethics to turn from medi-
cine's traditional attempt to eliminate 
suffering and take up the challenge of 
finding meaning in suffering. 
This is a valuable collection of 
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essays, primarily because it emphasizes 
the problem of suffering. Over the 
years philosophers and theologians 
have devoted their attention largely 
the problem of evil as a logical conun 
drum, while health-care givers have 
devoted their attention to the problem 
of pain, and relief of physical discom-
fort. Both concerns broach, but do not 
directly address, the experience of 
suffering as a threat to personal 
meaning, and that is precisely the 
concern of this book. Among its central 
features are the following. First, it 
acknowledges the complexity of the 
problem. Suffering is inevitable and 
inexplicable. It admits of no easy 
solutions. Second, in calling for a 
practical theodicy, and doing theodicy, 
the collection values theodicy-the 
traditional attempt to locate suffering 
within a framework of cosmic 
meaning. Although the collection 
challenges traditional theodicy in 
various ways, it does not reject the 
enterprise out of hand. If suffering is 
more than pain, a distinction made 
more than once in this collection, then 
theodicy's attempt to find meaning ir 
suffering, itself "represent[s] a kind ( 
relief from suffering." Third, it draws 
on the reflections of various thinkers, 
religious and non-religious, clinicians 
as well as philosophers and theolo-
gians. Fourth, the discussion substanti-
ates the "postmodern" insight that 
meaning lies in the realm of the 
individual and the particular, rather 
than the general, and finds natural 
expression in narrative rather than 
discursive forms of speech. 
Although the book has many of 
the virtues of a symposium, it also has 
some of its characteristic shortcom-
ings. The general theme is practical 
theodicy, but it is not clear that this is 
the concern of all the essays. The last 
three pieces in particular seem to go 
in different directions. In addition, 
the different essays place varying 
demands on the reader. Some are 
highly readable, while others contain 
tightly constructed arguments. 
In all, the book is an important 
contribution to the ongoing quest f, 
greater under~tanding of and morL.~ 
effective ways to respond to suffering. 
I'm glad I read it, I recommend it, and 
I'll use it in my classes ... 
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Changing our Genes: 
Medical Promises and Ethical Threats 
by Anthony J. Zuccarelli, PhD 
During the last two decades genetics has emerged from 
the research laboratory to become a powerful biomedical 
technology. Public awareness of the uses and potential misus-
es of genes and genetic information has grown as a result of a 
rapid-fire series of high-impact applications-DNA finger-
printing, presymptomatic genetic testing, genetically modi-
fied food plants, animal cloning, human embryonic stem cell 
lines, transgenic animals, the Human Genome Project and 
human gene therapy. The pace and sophistication of these 
advances has led some to predict that the next 50 years will 
witness an explosion of genetic applications rivaling those 
from physics, chemistry and the material sciences in the 
previous half-century. Gene therapy, as one of these 
interconnected developments, promises enormous benefits 
for treating human disease. But what hazards and ethical 
dilemmas follow in its train? 
Gene therapy is the introduction of genetic material into 
human patients in order to alter the expression of particular 
genes. The goal of these alterations is to treat, cure, or ulti-
mately prevent a disease or disability. Gene therapy should 
not be confused with cloning, which has overwhelmed the 
ublic media in recent years. Human cloning would result in 
l1e birth of an individual with essentially the same genetic 
makeup as an existing person. It is distinctly different from 
gene therapy, both scientifically and ethically. 
In this discussion I will describe some basic features and 
define two major classes of gene therapy. After reviewing 
methods that may be used to introduce new genes into 
humans, we will examine a few concrete examples, and final-
ly focus on the ethical concerns raised by the prospect of 
putting new genes into people. 
At the start, let's examine several features of gene thera-
py. In view of the rapid pace of developments, I have pro-
jected current capabilities into the near future. There is little 
question that these improvements will occur, only when and 
how they will occur. 
1. The introduced genetic material may be DNA, RNA, 
or a modified form of these molecules. (Elsewhere I may use 
"genes" or simply "DNA" to refer to all of these substances.) 
Recall that DNA is the permanent storage medium for genet-
ic information in cells. RNA is a versatile molecule, perform-
ing a variety of cellular tasks, but its best-known function is to 
carry selected bits of genetic information from the DNA in 
the nucleus to the protein factories that reside in the cell body 
(cytoplasm). 
2. The introduced genetic material may come from 
almost any source- humans, animals, plants, microbes, virus-
;-or it may be entirely synthetic with no counterpart in 
nature. Later examples illustrate a few of these possibilities. 
3. In current trials the added genetic material is usually 
supplemental, an addition to the patient's genome that corre-
sponds to defective or poorly expressed genes already pre-
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sent. However, considerable effort is directed at developing 
"gene targeting" in which the introduced material will pre-
cisely replace the defective gene. 
4. Strictly speaking, the introduced genetic material is 
not itself therapeutic. In most cases it influences the amounts 
of various proteins that cells make. The proteins are the 
molecular machines that accomplish the desired change. 
5. The new genetic material may have an intentionally 
temporary effect or it may be permanent. A genetic treatment 
for an acute condition, infectious disease, or cancer, for exam-
ple, might be deliberately short-term. On the other hand, a 
patient with an inherited or chronic disease may need life-
long therapy. Eventually we can expect genetic therapies to 
be configured to respond dynamically to the patient's condi-
tion so that they are expressed when needed. 
There are two broad categories of gene therapy, distin-
guished by the particular tissues that are modified. Somatic 
gene therapy targets the body cells of the patient, any organ 
or tissue other than the reproductive cells. Tissues in many 
different organs have been proposed for somatic gene thera-
py-bone marrow, liver, muscle, skin, thyroid, intestinal 
epithelium, lungs, blood vessels, heart, brain, etc. Somatic 
therapy has the same intent as conventional medicine-to 
relieve the suffering or save the life of the patient under treat-
ment. There is no attempt to produce an effect that extends 
beyond the individual patient. In fact, heritable effects are 
specifically and conscientiously avoided. 
The methods of somatic gene therapy are experimental, 
but the pace of investigation is rapid and vigorous. By the end 
of 1999, about 400 gene therapy trials involving over 3,200 
patients had been approved in the United States. 
Nevertheless, substantial improvements must be achieved 
before any particular application can be used outside a clini-
cal study. 
Germline gene therapy, on the other hand, would 
make genetic changes that extend to the reproductive or 
germ cells that develop into eggs or sperm. Such alterations 
could be transmitted to the offspring of the original patient. 
In fact, that is an intentional goal of germline therapy. It seeks 
to achieve a fundamentally new objective for a medical treat-
ment, the heritable correction of the genome. 
Germline therapy offers a significant advantage over 
somatic gene therapy in that it eradicates the genetic cause of 
a disease condition and prevents it from being propagated to 
offspring. Some argue that only germline treatments produce 
real cures, rather than the palliative or symptomatic treat-
ment of individuals.' A consequence of such therapy is that 
the health care system is relieved of treating successive gen-
Anthony J. Zuccarelli, PhD 
professor, microbiology/molecular genetics 
School of Medicine 
Loma Linda University 
3 
erations of affected individuals from the same family. 
Germline therapy has not yet been attempted in humans 
and, indeed, no one knows how to accomplish it efficiently or 
safely. Experience with germline modifications of laboratory 
and domesticated animals suggests that it may be some time 
before such alterations can be attempted in humans. 
Nevertheless, the NIH and the FDA have begun preliminary 
study of a proposal to treat a fetus in utero,2 and a March 1998 
symposium at UCLA brought together the thought-leaders 
of genetic medicine to consider the feasibility and advantages 
of germline therapy.3 
potentially initiate cancer. 
Non-viral vectors. There are several alternatives to 
using viruses. Liposomes, lipid-DNA complexes and bare 
DNA have some promising applications. So far, these ha~ 
proven much less efficient in most situations. It is possib , 
that a better understanding of how viruses enter cells may be 
useful in designing artificial agents that mimic their efficien-
cy and specificity, but avoid their deficiencies. 
In vivo and ex vivo methods. The gene delivery prob-
lem has had an impact on how gene therapy is performed. In 
vivo gene therapy, where the 
Somatic gene therapy, for its part, 
has come under intense scrutiny since 
September 1999, after the death of 18-
year-old Jesse Gelsinger, a participant 
in a clinical trial at the University of 
Pennsylvania.4 The deaths of several 
"The challenge has been to put 
these genes into the cells where 
they would be most useful." 
genetic material is introduced 
directly into the patient, has been 
very disappointing. Not enough of 
the patient's cells are effectively 
treated. Consequently, most early 
participants in other trials, attributed to their underlying dis-
ease, have also come to light. These incidents emphasize the 
need for more animal testing, better risk assessment, 
improvements in informing participants of risks, full report-
ing of adverse events, and ways to minimize the influence of 
commercial interests on the trials. Most commentators pre-
dict, however, that these cases will not stop further experi-
mentation, but intensify the search for improved methods. 
How might therapeutic DNA be introduced into 
patients? For more than 20 years we have been able to isolate 
genes that could provide clinical benefits-clotting factor 
genes for hemophiliacs, growth factor genes to accelerate 
wound healing, insulin genes for type I diabetics, tumor sup-
pressor and cytokine genes for cancer treatment, and genes 
for arterial growth to help patients with coronary disease. The 
challenge has been to put these genes into the cells where 
they would be most useful. The "delivery problem" -get-
ting genes into cells-is a major technical roadblock to suc-
cess. At present there are two basic approaches. 
Viral vectors. Virus-mediated gene transfer involves 
packaging therapeutic genes into engineered virus particles 
that can carry them into patient cells. These vectors exploit 
the incredibly efficient mechanisms that viruses use to intro-
duce their own genes into cells during infection. Three dif-
ferent virus groups have been used widely-Ientiviruses and 
other retroviruses (relatives of HIV), adenoviruses (common 
cause of "colds" and conjunctivitis) and adeno-associated 
virus (unrelated to adenoviruses and not known to cause 
human disease). Other virus groups are also under considera-
tion. Typically, the virus is disabled by removing all or part of 
its genome so that it cannot kill or proliferate in the cells it 
enters, unless that is a desired result. One or more therapeu-
tic genes replaces the viral material. 
All existing viral vectors suffer from practical limitations. 
The tendency of adenoviruses to provoke severe immune 
responses in sensitized patients was the likely cause of Jesse 
Gelsinger's death. Furthermore, genes carried by adenovirus 
vectors usually have only a temporary effect because this 
virus enters cells that have a short life in the body. Vectors 
based on the small adeno-associated virus offer very limited 
space for therapeutic genes, but they may provide a more sus-
tained effect. Lentiviruses and other retroviruses may disrupt 
normal genes in the patient genome and such changes could 
4 
trials were performed ex vivo-
outside the patient. In this approach, cells from a target tissue 
are obtained from the patient. Genetic material is introduced 
into these cells as they grow in culture using any of the means 
described earlier. Successfully modified cells are selected and 
expanded by further growth in culture. Finally they are 
returned to the patient so that they can colonize a target tis-
sue. Direct in vivo treatment is the long-term goal because of 
its simplicity and economy. E x vivo treatments represent a 
transitional expedient that will be used until the efficiency of 
vectors improves enough for in vivo use. Germline modifica-
tions, for comparison, would be performed in the undefined 
realm between in vivo and ex vivo-genes must be physicallv 
introduced into a zygote (pre-embryo) or into the four-t 
eight cell embryo in the laboratory. 
The wide range of potential applications for gene thera-
py is best illustrated by describing a few examples of attempt-
ed or proposed uses. 
Retroviral therapy for adenosine deaminase defi-
ciency. The first authorized attempt at gene therapy was to 
treat a rare genetic defect, deficiency of the enzyme adeno-
sine deaminase. Absence of this enzyme causes accumulation 
of a substance that poisons essential cells of the immune sys-
tem. The resulting severe combined immune deficiency syn-
drome (SCIDS) leaves the sufferer exquisitely susceptible to 
infections by even the mildest pathogens. SCIDS patients 
usually do not survive early childhood. (You may remember 
photos of David who lived to age 12 inside a sterile plastic 
bubble.) In 1990 Michael Blaese and French Anderson con-
structed a modified retrovirus to carry a functional copy of the 
human adenosine deaminase gene. They used the virus to 
introduce the gene into bone marrow cells extracted from a 4-
year-old SCIDS sufferer, Ashanti DeSilva, then returned the 
treated cells to the patient. Presence of the genetically modi-
fied cells contributed to measurable improvements in her 
immune system. Ten years after her initial treatment, Ashanti 
now attends school and participates in the activities of a typi-
cal 14-year-old with no more than an occasional cold. But 
genetic therapists cannot claim a cure. The treated blood cel' 
act for only a few months, so the process must be repeate 
periodically. Furthermore, Ashanti continues to receive oral 
supplements of the missing enzyme.s In 1999, two nine-
month-old boys with SCIDS were given new genes in 
France. They now have immune cells that were missing 
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before treatment and the constant infections that they suf-
fered since birth have disappeared. 
Drug activation gene to kill cancer. Gancyclovir, an 
r nntiviral drug, kills cells infected with herpes virus because 
. i_he virus makes an enzyme, called thymidine kinase, that 
converts gancyclovir into a cellular poison. One gene therapy 
experiment used this reaction to kill glioblastoma brain 
tumors. The thymidine kinase gene was put into a retrovirus 
vector that was injected into the tumor. Because these 
retroviruses could infect only dividing cells, they attacked 
proliferating tumor cells rather than normal, quiescent brain 
cells. Later, the patient was given gancyclovir, which 
specifically killed the tumor cells with viral thymidine kinase. 
The treatment was even more effective than expected due to 
the so-called "by-stander effect" in which gancyclovir kills 
both sensitized cancer cells as well as their nearest neighbors. 
The method is now being tested on several other cancer 
types. , 
DNA immunization. Naked DNA coding for proteins 
that appear on the surface of a pathogen can function like a 
vaccine. Unexpectedly, when DNA is injected directly into 
muscle some of it enters cells surrounding the injection site. 
If the DNA is properly designed, these cells will express the 
genes for a time, secreting the corresponding proteins and 
displaying them on their surfaces. Since the new proteins are 
from a pathogen and are not normally found in the body, they 
are identified as "foreign" by the immune system and target-
ed by antibodies and phagocytic cells. The immunological 
. "memory" of this event can protect the person from infection 
, ) y a real pathogen that displays the same proteins. 
; p53 skin cancer cream. There are about 100,000 new 
cases of squamous cell skin cancer in the United States each 
year, most due to excessive exposure to sunlight. After a sun-
burn, skin "peels" because a gene called p53 triggers the 
death of cells that have suffered severe UV damage. 
Programed cell death is a desirable protective response to 
DNA damage. However, if the p53 gene were itself inacti-
vated in some earlier event (like a childhood sunburn), its 
protective function would be lost. Cells with p53 defects 
have taken the first steps on the pathway to cancer because 
they survive subsequent genetic damage. One proposed 
genetic therapy is a skin cream that contains copies of the p53 
gene in liposomes. Applied to the skin, the supplementary 
p53 gene would cause the immediate self-destruction of pre-
cancerous cells. The treatment would be used on individuals 
at risk for skin cancer or with history of pre-cancerous lesions. 
Viral mediated gene therapy for cystic fibrosis. The 
most serious manifestation of cystic fibrosis is the suscepti-
bility of sufferers to frequent lung infections. These cause 
inflammation, destruction of lung tissue, respiratory failure, 
and premature death. The underlying defect is in the CFTR 
gene that is normally responsible for regulating the flow of 
ions across cell membranes. The gene was isolated in 1992 
and has been engineered into a recombinant adeno-associat-
-ed virus. The original virus genome was eliminated to make 
/oom for the CFTR gene. Applying the virus to airway 
epithelial cells in the form of an inhalant can reverse the defi-
ciency and avoid the most severe consequences of the dis-
ease. 
Ethical considerations. Laudably, the Human 
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Genome Program was the first national science initiative to 
specifically designate a portion of its budget for systematic 
examination of the ethical, legal and social implications of 
genetic technology. One consequence of the resulting dis-
cussions is the general acceptance of the proposition that the 
introduction of therapeutic genes into somatic cells is con-
ceptually similar to the transplantation of cells or organs, or 
the implantation of artificial medical devices. It raises the 
same ethical and social issues as those widely used medical 
procedures. 
1. "Do no harm" is the first principle of medicine. A 
treatment must offer a measurable prospect of benefit, and 
that benefit must outweigh the possibility of adverse events. 
The requirement for a favorable risk/benefit analysis is for-
mally embedded in the clinical testing program of the United 
States. Somatic therapies will emerge from clinical trials 
when there is good evidence that they offer solid benefits and 
avoid significant harm. 
On the flip side, since somatic genetic therapies may 
always impose some inherent risk, they should probably not 
be used to alter conditions that are not life-threatening nor 
severely disabling. In spite of public demand and possible 
financial inducements, using genes to engineer cosmetic 
enhancements-like reversing pattern baldness or changing 
superficial appearance-should not be considered until the 
attendant risk approaches zero. I would hope that genetic 
medicine could avoid the excesses of cosmetic surgery. 
The risk/benefit calculus becomes more complex in 
germline gene therapy because we cannot foresee all the con-
sequences of permanent human genetic modifications. We 
know too little about the multiple roles of individual genes, 
and the proteins they make, in highly interactive living sys-
tems. Some consequences may not become apparent for 
years or even generations. Will the eradication of a genetic 
feature deemed undesirable because of its primary effect also 
eliminate some secondary, but highly valued, trait? 
This concern, however, may be addressed by recent pro-
posals that would permit patients, under medical supervision, 
to reverse gene additions non-invasively. There are several 
molecular systems that could accomplish the feat of 
precisely excising an artificially introduced DNA segment 
and sealing up the gap. An oral drug, similar to an antibiotic 
or hormone, could trigger the enzymatic reversal. Like the 
"uninstall" option on your computer, individuals would be 
able to undo genomic changes made by their progenitors, or 
exchange them for more recent versions.6 
2. Christian healing commission. A second principle is 
the Christian obligation to alleviate suffering and preserve 
life. The Scriptures portray God as endlessly concerned with 
the moral and physical restoration of his creatures. "And he 
sent them to preach the kingdom of God, and to heal the 
sick" (Luke 9:2). Christ gave explicit instructions to continue 
his healing ministry. To the extent that it can prevent disease 
and restore health, we are obliged to investigate the potential 
of genetic therapies. Christian health professionals have a 
moral obligation to use the most effective methods to prevent 
or treat disease. 
3. Imago Dei. The doctrine of the image of God in 
humanity is a fundamental Christian belief. Though there 
may be disagreements among Christians as to what consti-
5 
tutes God's image, we generally hold that the distinctive traits 
that set us apart from other earthlife include abstract reason-
ing, appreciation of spiritual values, and the ability to make 
decisions based upon moral principles. We should avoid any 
genetic alteration that might interfere with these capacities.7 
Some claim that genetic technology offends or violates 
the "natural order." Respect for God and created life, 
however, does not preclude human intervention in nature. 
Humankind has regularly abandoned the course of nature. 
Our world includes heart disease, diabetes, cancer and AIDS. 
Few would argue that these particular manifestations of 
nature are good or that we should allow 
organ transplantation, advanced forms of assisted reproduc-
tion, and various surgical techniques. This is a health policy 
issue that must be addressed adequately before we can claim 
to be a fair and just society. 
6. God endowed human beings with intelligence an" 
creativity, and charged us with responsibility for the planet. 
He intends for us to grow in our understanding of the princi-
ples of life, including the function of our bodies. Ethical 
research and examination can only increase our appreciation 
of God's wisdom and goodness. 
As no other creatures on earth, we persist in probing and 
questioning, attempting to understand 
them to progress unopposed. From the 
Christian perspective, nature is not 
God, that it should be worshiped. On 
the contrary, we are assigned the task of 
preserving the good in nature and 
restoring humanity to a condition in 
"Respect for God and created 
life, does not preclude human 
intervention in nature." 
nature and make it accountable. Within 
the medical realm, we are powerfully 
driven to control disease--conditions 
that disrupt the order and harmony that 
God intended. We are invited to use 
which it can appre~iate the character and goodness of God. 
4. Human autonomy. God places enormous value on 
human freedom. For this reason genetic alterations that 
would limit an individual's abilities, restrict participation in 
society, reduce autonomy, or undermine personal freedom 
must be rejected. Autonomy may be violated if germline 
therapy is attempted without a means for reversal. This prin-
ciple also supports the development of genetic therapies as a 
means to satisfy the needs of prospective parents, at risk for 
transmitting serious genetic diseases, to bear healthy chil-
dren. Pressure to use germline gene therapy, for example, 
"will not likely come from government or dictators with a 
desire to make a super race, but rather from parents who 
desire to improve the chances of their biological children." 6 
The principle of autonomy requires informed consent. 
Patients must be able to weigh the potential risks and advan-
tages and freely select a course of action without coercion or 
duress. The ability to give informed consent may itself be 
undermined if genetic therapists are unable to predict with 
confidence the long-range effects of a genetic change. 
Consequently, reliable means for reversing an alteration will 
be essential, especially for germline therapy, since unintend-
ed consequences may not appear or be appreciated for many 
years. 
Finally, irreversible germline modifications would violate 
the rights of subsequent generations to inherit an unmodified 
genome. Thoughtful, unconstrained individuals may make 
different choices regarding artificial changes in their genes. 
The therapeutic choice of one generation should not unduly 
limit the options of the next. Without mechanisms to activate 
a genetic therapy at the age of majority, and the ability to 
undo genetic modifications, germline changes raise the issues 
of genetic determinism, loss of uniqueness and the failure of 
informed consent. 
5. Justice. Some question whether access to gene thera-
py will be allocated equitably. Can we afford such expensive 
treatments at a time when our health-care system is strained? 
Who should receive it? If it is available only to those who can 
afford it, will the distribution of desirable traits become badly 
skewed among different groups in society? These questions 
point out a general flaw in our health-care system since they 
apply with equal force to other advanced medical services-
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the knowledge he gives us. 
Consequently, gene therapy need not be an expression of 
human pride or arrogance. As long as the aim is to alleviate 
suffering, and we use our creativity with purpose, courage, 
caution, contingency and compassion, keeping in mind the 
protection of the defenseless and helpless, genetic medicine 
has the same moral justification as traditional medicine. On 
the other hand, an attempt to redesign ourselves into crea-
tures with new and superlative powers would be perilous. A 
balanced view of our God-likeness should remind us that we 
tamper with fundamental human attributes at great risk. 
Many caution that the use of gene therapy will put us on 
a slippery slope with no dividing line between therapy an 
enhancement. In rebuttal, we do not prohibit every 
endeavor that, if pursued without restraint, might lead to 
undesirable consequences. Everything we do carries risks 
which we attempt to balance against the benefits of mea-
sured action. That is the domain of ethics. Our deliberation 
implies that we can prescribe limits for our behavior. The 
reflection of God's image that remains invites us to 
responsible action .• 
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Siegler of the University of Chicago if 
he thought Dr. Orr might serve Lorna 
r "\ inda well as a clinical ethicist. Dr. 
Jiegler's face beamed with joy as he 
assured me that we could make no bet-
ter choice. He was right! 
F or the past decade, we at Lorna 
Linda have enjoyed a wonderfully col-
laborative relationship between those 
of us who are primarily teachers and 
those of us who are primarily clinicians, 
something that is not always the case in 
the world of bioethics. The Clinical 
Ethics Service, the Center for Christian 
Bioethics and the Master of Arts pro-
gram in biomedical and clinical ethics 
all testify to the success of this relation-
ship. Dr. Orr's presence, personality 
and professionalism have done more 
than we can tell to make all this possi-
ble. 
We are going to miss Bob. We are 
also going to miss Joyce, his splendid 
partner. 
Nevertheless, even on solemn 
occasions like this one, honesty is 
required. This means we must concede 
.t"hat in some respects our relationship 
) ith Dr. Orr has been awkward. This is 
especially true with respect to his reli-
gious orientation, something about 
which there is good news, not-so-good 
news and very good news. 
The good news is that, like many 
of us, Dr. Orr received his basic reli-
gious education from people who are 
theological descendants of the eigh-
teenth century English reformers, John 
and Charles Wesley. Before studying 
medicine at McGill University, he 
attended a small liberal arts college in 
New York that is operated by those 
who descend theologically from these 
two brothers. 
Although many don't know it, and 
some apparently don't care, Seventh-
day Adventists are also part of the 
Wesleyan stream of Christian thought 
and life. Ellen White and other theo-
logical "grandchildren" of the Wesley 
brothers founded Lorna Linda 
University and many other medical and 
educational institutions around the 
"torld. Because we share this common 
!~ligious heritage, it has been easy to 
be comfortable when working with 
Bob. 
The not-so-good news is that Dr. 
Orr is not always as faithful to his 
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Wesleyan heritage as we would prefer. 
He has been known to fraternize with 
those who are Christians of different 
sorts: to speak well of them, to work 
with them and even to worship with 
them! 
Given his religious background, 
we expected that when he and Joyce 
moved to Southern California they 
would join a congregation belonging to 
anyone of the several Wesleyan 
denominations in our area. But they 
didn't! Each week they worship with 
another group of Christians whose 
name I shall not mention in this com-
pany. For many of us, this has been a 
source of intense perplexity and pain 
for ten long and difficult years! 
The very good news is that Dr. 
Orr's Wesleyan background surfaces in 
unmistakable ways even when none 
expect this to happen. This is a com-
forting verification of the words of 
Scripture, "train up a child in the way 
he should go, and when he is old, he 
shall not depart from it." 
Nowhere is this more evident than 
with respect to the question of human 
freedom. Strange though it may seem, 
Dr. Orr now associates with some 
Christians who actually believe in pre-
destination! Nevertheless, sometimes 
when we are least expecting it, the 
emphasis of his Wesleyan religious 
background on human freedom, and 
the uncertainty about the future it nec-
essarily implies, erupts from him in 
surprising but telling ways. 
I shall mention only one actual 
example, a report Dr. Orr gave us him-
self with his usual professional serious-
ness and self-criticism at one of our 
weekly Clinical Ethics Case 
Conferences. 
Dr. Orr revealed that since we last 
met he had been requested to visit an 
elderly woman in our medical center 
who was conscious though very near 
death. After discussing all the options 
as best they could, even though a res-
pirator was assisting her breathing, this 
patient, her gathered relatives and Dr. 
Orr all agreed that it would be best no 
longer to fight her approaching demise 
but to accept its inevitability with calm 
Christian dignity. 
Dr. Orr, as he always does in diffi-
cult cases like this one, explained to 
the patient what would happen. "We 
will give you some medicine that will 
enable to you to fall into a deep and 
comfortable sleep," he said. "While 
you are sleeping, we will gradually turn 
down the respirator. Without even 
knowing it, you will then stop breath-
ing. You will experience no grief, stress 
or discomfort as you peacefully slip 
away." 
At this poignant moment, one of 
the patient's loved ones exclaimed, 
"And the next thing you know, you will 
be with Jesus!" 
Dr. Orr quickly replied, "And 
maybe not!" He actually did! 
Dr. Orr thinks he knows why he 
startled everyone-the elderly patient, 
her relatives and even himself-by 
saying this. As he explained at our 
Clinical Ethics Case Conference with 
obvious embarrassment, he believes he 
was trying to make clear that not every 
patient who is extubated immediately 
expires. Some continue breathing on 
their own for a while longer, a few for 
many more years. 
But I know the real reason why Dr. 
Orr said, "And maybe not!" In his 
heart of hearts, despite his more recent 
religious wanderings, he is still a 
Wesleyan! As such, he senses, even if 
he is not always consciously aware of it, 
that because of human freedom the 
future is somewhat uncertain for all of 
us! 
Thank you Bob for ten wonderful 
years! Jerry Winslow left Lorna Linda 
for four years and then returned. I 
hope that someday you will come 
"home" too! 
Note: After these comments, Dr. Orr 
said he would return to Loma Linda if 
"this is predestined!" .. 
Bioethics Grand Rounds 
November 8,2000 
Ethical Issues in Professional 
Practice: The Problem of 
Multiple Relationships 
Speaker: 
Janet Sonne, PhD 
12 noon to 1 P.M. 
A-Level Amphitheater 
Lorna Linda University 
Medical Center 
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ethics with Dr. Mark Siegler and oth-
ers at the University of Chicago. After 
completing this program, they moved 
to Redlands, California and Dr. Orr 
joined the faculty at Lorna Linda. 
At first Dr. Orr divided his time 
between family medicine and clinical 
ethics. Although he retained his appoint-
ment in family medicine, as the years 
went by and the demands for his con-
sulting services increased, he invested 
increasing amounts of his time in the 
area of clinical ethics. His work as a clin-
ical ethicist has been financed by the 
medical center's administration. 
In addition to his work on cam-
pus, Dr. Orr has been an active leader 
in the California Medical Association, 
the Christian Medical and Dental 
Society and the American Society of 
Bioethics and the Humanities. 
Dr. Orr successfully led a transi-
tion from a "committee approach" to a 
"consultant approach" in clinical 
ethics at Lorna Linda University 
Medical Center. In the vast majority of 
cases, the Institutional Ethics 
Committee at LL UMC no longer con-
ferred about difficult ethical issues 
pertammg to patient care. Instead, 
health care professionals, as well as 
patients and their families, called for 
professional counsel from Dr. Orr a 
the clinical colleagues he mentoreL.. 
Once each week, the entire team of 
ethicists at Lorna Linda, both clinical 
and theological, met to discuss cases in 
which Dr. Orr and his associates 
recently served as consultants. For a 
decade, this arrangement has success-
fully blended the greater efficiency of 
the "consultant approach" with the 
advantages of collaboration in the 
"committee approach.". 
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